source
- Sanofi pauses Phase 2 bronchiectasis study of SAR445399 amid new CEO’s portfolio reviewSanofi has halted a Phase 2 trial of its investigational antibody SAR445399 in non‑cystic fibrosis bronchiectasis. The pause was attributed to strategic business reasons linked to an internal portf…
- BioVie shares plunge as Parkinson’s trial results lack primary motor dataBioVie reported results of its Phase 2 SUNRISE-PD study in early‑stage Parkinson’s disease. The double‑blind, placebo‑controlled trial enrolled 57 patients who had not yet received carbidopa/levodo…